Circulating endothelial cells as biomarkers in clinical oncology

Patrizia Mancuso; Francesco Bertolini

doi:10.1016/j.mvr.2010.02.007

Circulating endothelial cells as biomarkers in clinical oncology

Patrizia Mancuso, Francesco Bertolini

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article › peer-review

Abstract

Circulating endothelial cells (CECs) and circulating endothelial progenitors (CEPs) play a different role in cancer development, acting as possible markers of vascular turnover/damage (CECs) and vasculogenesis (CEPs). Preclinical and clinical data suggest that CEC enumeration might be useful to define the best treatment option for patients who are candidate to anti-angiogenic therapy, while CEPs seem to have a "catalytic" role in different steps of cancer progression and recurrence after therapy. The definition of CEC and CEP phenotype and the standardization of CEC and CEP enumeration procedures are highly warranted to use these cells as biomarkers in clinical trials in oncology, and to compare results from different studies.

Original language	English
Pages (from-to)	224-228
Number of pages	5
Journal	Microvascular Research
Volume	79
Issue number	3
DOIs	https://doi.org/10.1016/j.mvr.2010.02.007
Publication status	Published - May 2010

Keywords

Angiogenesis
Endothelial cells
Endothelial progenitors

ASJC Scopus subject areas

Biochemistry
Cell Biology
Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.mvr.2010.02.007

Fingerprint Dive into the research topics of 'Circulating endothelial cells as biomarkers in clinical oncology'. Together they form a unique fingerprint.

Cite this

@article{b7a334dde6164c2fbc2dd6997cf47506,

title = "Circulating endothelial cells as biomarkers in clinical oncology",

abstract = "Circulating endothelial cells (CECs) and circulating endothelial progenitors (CEPs) play a different role in cancer development, acting as possible markers of vascular turnover/damage (CECs) and vasculogenesis (CEPs). Preclinical and clinical data suggest that CEC enumeration might be useful to define the best treatment option for patients who are candidate to anti-angiogenic therapy, while CEPs seem to have a {"}catalytic{"} role in different steps of cancer progression and recurrence after therapy. The definition of CEC and CEP phenotype and the standardization of CEC and CEP enumeration procedures are highly warranted to use these cells as biomarkers in clinical trials in oncology, and to compare results from different studies.",

keywords = "Angiogenesis, Endothelial cells, Endothelial progenitors",

author = "Patrizia Mancuso and Francesco Bertolini",

year = "2010",

month = may,

doi = "10.1016/j.mvr.2010.02.007",

language = "English",

volume = "79",

pages = "224--228",

journal = "Microvascular Research",

issn = "0026-2862",

publisher = "Academic Press Inc.",

number = "3",

}

TY - JOUR

T1 - Circulating endothelial cells as biomarkers in clinical oncology

AU - Mancuso, Patrizia

AU - Bertolini, Francesco

PY - 2010/5

Y1 - 2010/5

N2 - Circulating endothelial cells (CECs) and circulating endothelial progenitors (CEPs) play a different role in cancer development, acting as possible markers of vascular turnover/damage (CECs) and vasculogenesis (CEPs). Preclinical and clinical data suggest that CEC enumeration might be useful to define the best treatment option for patients who are candidate to anti-angiogenic therapy, while CEPs seem to have a "catalytic" role in different steps of cancer progression and recurrence after therapy. The definition of CEC and CEP phenotype and the standardization of CEC and CEP enumeration procedures are highly warranted to use these cells as biomarkers in clinical trials in oncology, and to compare results from different studies.

AB - Circulating endothelial cells (CECs) and circulating endothelial progenitors (CEPs) play a different role in cancer development, acting as possible markers of vascular turnover/damage (CECs) and vasculogenesis (CEPs). Preclinical and clinical data suggest that CEC enumeration might be useful to define the best treatment option for patients who are candidate to anti-angiogenic therapy, while CEPs seem to have a "catalytic" role in different steps of cancer progression and recurrence after therapy. The definition of CEC and CEP phenotype and the standardization of CEC and CEP enumeration procedures are highly warranted to use these cells as biomarkers in clinical trials in oncology, and to compare results from different studies.

KW - Angiogenesis

KW - Endothelial cells

KW - Endothelial progenitors

UR - http://www.scopus.com/inward/record.url?scp=77952093536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952093536&partnerID=8YFLogxK

U2 - 10.1016/j.mvr.2010.02.007

DO - 10.1016/j.mvr.2010.02.007

M3 - Article

C2 - 20176038

AN - SCOPUS:77952093536

VL - 79

SP - 224

EP - 228

JO - Microvascular Research

JF - Microvascular Research

SN - 0026-2862

IS - 3

ER -